Updated Jul 16, 2026
FRATES JAMES M is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $396K.
James M. Frates is the Chief Financial Officer of Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases. He has also held a similar role at Sage Therapeutics, Inc.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | AMLX | Amylyx Pharmaceuticals, Inc. | A — Grant or award | 96.0K | $0.00 | |
| 2026-03-04 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 7.9K | $14.52 | $115K |
| 2026-02-04 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 3.6K | $14.65 | $52K |
| 2026-01-08 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 3.3K | $11.11 | $37K |
| 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 10.6K | $14.65 | $155K |
| 2025-07-31 | SAGE | Sage Therapeutics, Inc. | J — Other acquisition / disposition | 2.8K | — | |
| 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 10.9K | $3.47 | $38K |
James M. Frates is the Chief Financial Officer of Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases. He has also held a similar role at Sage Therapeutics, Inc.…
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($396K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live FRATES JAMES M profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.